inobrodib

Inobrodib (CCS1477) is an orally bioavailable, small molecule inhibitor that selectively targets the bromodomains of the histone acetyltransferase paralogs p300 and CREB binding protein (CBP). By binding to these conserved bromodomains, inobrodib disrupts the recruitment of p300/CBP to chromatin regions critical for oncogenic transcriptional programs. This leads to downregulation of key cancer-driving genes such as MYC and IRF4, induction of cell-cycle arrest, and promotion of differentiation in hematologic malignancies. In prostate cancer models, it inhibits androgen receptor signaling by blocking p300/CBP activity. Inobrodib has demonstrated preclinical efficacy as monotherapy and synergistic effects when combined with standard-of-care agents like lenalidomide or BET inhibitors. It is being developed primarily for hematological malignancies (including multiple myeloma and acute myeloid leukemia) and castration-resistant prostate cancer.

Other names

inobrodib